Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced pelvic paraganglioma presenting as hematuria and urinary retention with a large intravesical mass: A case report.

Urology case reports·2026
Same author

Analyzing the impact of ionizable lipid identity, purity, and stability on lipid nanoparticle performance.

Journal of pharmaceutical and biomedical analysis·2026
Same author

In honor of Prof. Véronique Préat.

Drug delivery and translational research·2026
Same author

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

Cancer cell·2026
Same author

Identification of Circulating Lipidomic Biomarkers of Malnutrition Risk among Oncology Patients in the Total Cancer Care (TCC) Study: A Cross-Sectional Analysis.

The Journal of nutrition·2026
Same author

Cardiovascular Disease in a Population-Based Cohort of Prostate Cancer Patients With Long-Term Follow-Up.

Clinical genitourinary cancer·2026

Related Experiment Video

Updated: Jun 18, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Chitosan-based nanostructures: a delivery platform for ocular therapeutics.

Maria de la Fuente1, Manuela Raviña, Patrizia Paolicelli

  • 1Department of Pharmaceutical and Biological Chemistry, University of London, The School of Pharmacy, WC11AX London, UK.

Advanced Drug Delivery Reviews
|December 5, 2009
PubMed
Summary

Novel chitosan-based nanosystems offer advanced drug delivery for eye disorders. This nanotechnology platform enhances drug interaction, overcomes ocular barriers, and prolongs therapeutic residence time for effective treatment.

More Related Videos

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Related Experiment Videos

Last Updated: Jun 18, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Area of Science:

  • Ophthalmology
  • Nanomedicine
  • Drug Delivery Systems

Background:

  • Nanotechnology offers novel therapeutic strategies for ocular disorders.
  • Nanocarriers improve drug interaction with ocular structures and prolong residence time.
  • Effective topical ocular drug delivery faces significant challenges.

Purpose of the Study:

  • To develop and evaluate a chitosan-based nanodelivery platform for topical ocular drug delivery.
  • To adapt nanosystems for delivering both hydrophilic and lipophilic drugs, and polynucleotides.
  • To assess the potential of this platform for treating ocular disorders.

Main Methods:

  • Design and development of a chitosan-based nanocarrier system.
  • Adaptation of nanosystems for various therapeutic molecules (hydrophilic/lipophilic drugs, polynucleotides).
  • Evaluation of interaction with ocular structures and barrier penetration.

Main Results:

  • Chitosan nanosystems demonstrate suitability for topical ocular administration.
  • The platform facilitates delivery of diverse therapeutic agents to the eye surface.
  • Promising results indicate potential for enhanced ocular treatment efficacy.

Conclusions:

  • Chitosan-based nanosystems represent a promising platform for ocular drug delivery.
  • Further preclinical evaluation is necessary to meet regulatory requirements for ocular administration.
  • This nanotechnology approach holds potential for advancing the treatment of various eye conditions.